AstraZeneca Expands Biotech Capabilities with Amgen Plant Buy

Oct. 11, 2016

London-based AstraZeneca has purchased a 70-acre Amgen campus in Longmont, Colorado for $64.5 million.

AZ says it will immediately begin utilizing the space to warehouse items needed to support manufacturing operations in Boulder, a site which the drugmaker is renovating to produce its experimental bladder cancer drug, durvalumab.

“The Longmont facility adds to our expanding biologics commercial manufacturing capabilities as we prepare for our exciting future biologic medicines,” Darren Dasburg, site director of AstraZeneca’s Boulder Manufacturing Center told the Denver Business Journal.

The purchase includes two labs, a warehouse, a utilities plant and a manufacturing facility. AZ also purchased 159 acres of vacant land adjoining the property.

Read the Denver Business Journal coverage